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Commentary
Geffen Faculty Highlight Concerns Linking CAIM and Conventional
Researchers at UCLA Symposium
Elizabeth H. Logue
UCLA Center for East West Medicine, Santa Monica, CA 90404, USA
David Geffen School of Medicine faculty, representing a wide range of disciplines, engaged
speakers nationally known for their expertise on complementary, alternative and integrative
medicine (CAIM) and its investigation at a January, 2008 symposium on the campus of
the University of California, Los Angeles. The forum was created to educate the UCLA
Institutional Review Board (IRB), and lively participation by School of Medicine faculty helped
bring IRB members up to speed on controversies surrounding CAIM research. The symposium
demonstrated that academics who are neither proponents nor detractors of CAIM can facilitate
cross talk between opposing camps, elucidating questions important to its evaluation by those
charged with protecting research subjects. It also brought attention to the universality of
quandaries facing CAIM investigators and to the ingenuity with which they have addressed
many of them.
Keywords: attitudes towards CAM – cost-benefit analysis – double blind randomized controlled
clinical trial – experimental study – quality of life trials
‘Science of CAIM: What’s Next for Complementary,
Alternative and Integrative Medical Research?’ a UCLA
symposium meant to acquaint Institutional Review
Board (IRB) members with controversies surrounding
CAIM’s investigation focused first on regulation (1).
Thanks largely to input from David Geffen School of
Medicine faculty, however, the January, 2008 event
blossomed into a thoughtful airing of a broad range of
questions facing both CAIM and conventional research-
ers. Dr Daniel Cherkin of Group Health, Seattle, gave
a cogent introduction to the topic. Noted CAIM critic,
Dr Donald Marcus of Baylor College of Medicine and
Dr John Longhurst, Director of the Susan Samueli
Center for Integrative Medicine at the University of
California, Irvine then began by criticizing government
regulatory efforts. Dr Ary Goldberger, Director of the
Margret & H.A. Rey Institute for Nonlinear Dynamics
in Medicine at Harvard University followed, providing a
glimpse of where CAIM may be heading in describing
his own research. Then, UCLA faculty proceeded to give
the event its unique character with their questions and
comments, demonstrating equal interest in policy and
scientific concerns. The panelists included Distinguished
Professor of Neurobiology and Editor in Chief of eCAM,
Edwin L. Cooper; noted cancer researcher, Dr Patricia
Ganz; Professor of Neurology, Radiology, Psychiatry and
Biomedical Physics, Mark S. Cohen; geriatrics substance
abuse expert, Dr Alison Moore and pediatric pain
investigator, Dr Jennie Tsao. Although time prohibited
an in-depth exploration of most of the questions raised,
many were thought provoking and deserve further
consideration.
Some panelists homed in on the role played by politics
in the evolution of National Institutes of Health (NIH)
Centers. In this connection, it should be noted that
political considerations are crucial in determining health
priorities. In the CAIM world, advocates of traditional
medicine are sometimes at odds with those whose focus
is the complementary health practices of the more affluent.
Such conflict is generally salutary, the successes of AIDS
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Irrespective of the role of other stakeholders, the scientific
community will always play a leading part in determin-
ing the direction of NIH. One panelist’s contention that
scientists tend to band together in a closed, mutually
reinforcing fraternity thus merits comment. Like politics,
science is socially constructed and compelling arguments
suggest that it is positivistic and may therefore be ill
equipped to accommodate true innovation (4). It is worth
considering whether we need proponents of unorthodox
ideas simply to oppose any such tendencies.
Another panelist lent support to arguments about con-
servatism in science, citing peers’ unwillingness to look at
evidence linking the mind and body. Such skepticism
is especially ironic, given that the ‘humors’ paradigm
held sway in the West long after scientists elsewhere
had turned to what more closely resembles modern
experimental methodology (5). Today there is convincing
research showing that expectations influence outcomes
and that placebo analgesia leads to brain changes (6–8).
Rational people may disagree on the centrality of non-
specific effects or on the prescription of ‘inert’ treatment,
but it is a matter of concern when prejudice prevents a fair
hearing for even well grounded work on such questions.
While speakers criticized the National Center for
Complementary and Alternative Medicine (NCCAM) for
funding scientifically unsound research, some panelists
took exception to that critique. One noted that taxpayers
approve faith-based initiatives, implying that orthodox
notions of plausibility should not necessarily predominate
at NIH. This is a persuasive argument, but it is important
to remember that the scientific community’s view of plau-
sibility and how it should be determined is, itself, in flux.
For example, while the randomized trial has played an
important role, not least in providing an impersonal
method of assessment for modern, bureaucratic medicine
(3), its pre-eminent position has come into question. This
occurs as complexity science yields tools better able to
capture the effects of actual medical practice. Theoretical
physics, meanwhile, continues to attend closely to expert
opinion (3). Perhaps medicine will look to such examples as
it reconsiders the status of the ‘lesser’ forms of evidence.
Scientists are also revisiting the question of the order in
which studies should be undertaken. Because CAIM is
already used widely, many support investigation of effec-
tiveness before mechanism of action (9–12). While some in
academic medicine are uncomfortable with such change,
clinicians are pragmatic. MDs willingly used aspirin long
before learning how it worked and are likely aware that
there is little good evidence for many of the decisions they
must make (13,14). Whatever they may think of its scientific
plausibility, medical doctors, like average citizens, have
clamoredforinformationonCAIM(9).OneUCLApanelist
suggested that a natural ‘winnowing’ process would ulti-
mately succeed in identifying therapies of real value. This
makes sense and an analysis of the approach of others on
the same path could help expedite the process. The Hong
Kong Hospital Authority uses knowledge mapping to look
for areas in which biomedicine has proved weak but CAIM
therapies show promise. This may yield opportunities for
important collaborative research (15). Reimbursement is
based on safety, effectiveness and cost. Any means of
speeding up the identification of superior treatments—thus,
their availability—is worth pursuing (16,17).
Some CAIM modalities merit study not because they
have been identified by means of informatics but simply
because they are used regularly by millions. As one ‘Science
of CAIM’ participant remarked, what Americans call
‘complementary’ and ‘alternative’ is neither for many. It
is sometimes suggested that those using traditional medi-
cine do so because they have no choice. It is ethnocentric
to assume inferiority, however, especially given that some
traditional medical practices are clearly associated with
good health, as one conferee noted. Investigating uncon-
ventional medicine does present unique challenges, though,
including the problem of paradigm-appropriate design. If,
for example, a belief system posits bodily ‘hubs’, by which
treatment affects many targets, it may be necessary to
devise new outcomes to test its claims. Unfortunately, there
is a dearth of validated outcome measures for CAIM,
today (18,19). In dealing with such shortcomings, investi-
gators have found much that may prove valuable to
medical science as a whole. For example, methods devised
to examine multiple variables within whole systems can
inform studies of effectiveness (11,20). As we begin to
understand the multiplicity of factors implicated in healing,
targeted, cost-effective treatments follow (21,22).
While there may be consensus regarding the need to
look at the many contributors to illness and recovery,
UCLA participants suggested that when it comes to whole
systems of medicine, those elements should not be studied
piecemeal. Western science has operated in a reductionis-
tic fashion for some two centuries, but CAIM researchers
have asserted that applying conventional methods to whole
systems is similar to trying to understand how a computer
functions by smashing it and examining the pieces. Small
effect sizes for the subunits of such systems suggest that
this is an apt metaphor (10). To understand complexity in
any form, including multimodal biomedical practice, it is
crucial to be aware of the interaction among parts and
emergent properties (11,23–25). We now know the impor-
tance of the interplay among causes of gene expression (18).
Likewise, to understand complex, chronic disease, looking
at many factors simultaneously may be critical (22). For
example, Ahn has suggested that with diabetes we must
comprehend the interplay among inflammation, cortisol,
leptin, body mass index and so forth (26). The ultimate
question with respect to how parts of a multi-faceted
system affect one another, though, is what delimits the
system. Does it include friends, the health practitioner, the
environment or particular host factors? (18,27) What else
must be included? NCCAM is taking on the challenge of
30 Science of CAIMdevising new methods to study biological complexity as
well as complex systems, recognizing the need to look at
them holistically, so some answers to those questions are
likely to be forthcoming (28,29).
One member of UCLA’s faculty pointed out that
measurement instruments may not be sensitive enough
to detect CAIM’s effects, which highlights the problem
of how to get a fuller picture of the experience patients
report, whether of whole-system treatment or of less-
comprehensive alternative therapy. Measures of trans-
formational change, provider/patient match and other
factors making a single intervention differentially effec-
tive could be useful (25,30–32). To capture dynamism, it
might help to employ adaptive and sequential decision-
making study designs (21,33,34). Various life enhancing
effects of CAIM could be evaluated using quality-
adjusted life years, which also give a sense of cost effec-
tiveness (17,35). Individualization of treatment is another
factor commonly implicated in positive outcomes for
CAIM patients. As a focus of investigation, it has the
additional advantage that it could lead to a reduction in
the complications and waste occurring with general-
ization from homogeneous, highly responsive subjects
(10,14,26,36). Today, biomedicine tries to target therapy
based on organ function, hormone status, genomics and
proteomics, and ‘personalizing’ medicine is a major NIH
goal (18,22,37). Meanwhile, CAIM researchers champion
studies looking at within-subject change and have used
informatics to track individualized regimens (22,38,39).
Capturing the effects of patient-centered therapy will not
only help bridge the gap between negative studies and
positive patient reports but has great potential as an area
of cooperation between mainstream and CAIM investi-
gators as well.
While there are already some good, albeit underused
means of capturing patients’ experience of CAIM, a
panelist’s question as to how to handle small observa-
tional studies brings up the fact that numerous technical
difficulties remain for would be investigators. NCCAM
has specifically addressed the subject of small studies, but
what is the best way to correct for differences among
providers offering the same treatment or the optimum
dose for various parts of a whole system? In order to
accommodate prevailing conventions, is it best to look at
multimodal treatments together, then to examine them as
parts are removed—or will doing so corrupt results
irretrievably? (10,25) As the field matures, organizations
such the International Society for Complementary
Medicine Research can be expected to develop guidelines
addressing these and other problems involving design,
methodology and data analysis.
By inviting the commentary of persons highly critical
of CAIM research and regulation, ‘Science of CAIM’
succeeded in amplifying concerns underlying IRB preju-
dice, the existence of which has been suggested by NCCAM
and CAIM leaders (29,40). This, in itself, was a valuable
achievement. The contribution of UCLA faculty was
particularly noteworthy, however, due to the breadth of
its implications. Looking further into questions raised by
the panelists, it becomes apparent that CAIM scientists are
playing a pioneering role with respect to problems that
have stumped investigators of all persuasions (41–43).
Lively discussion of issues such as scientific plausibility,
paradigm-appropriate design and the research agenda
likely raised awareness of the common ground between
CAIM and mainstream science not only among IRB
members in attendance but also among stakeholders
in many of the Geffen School’s academic departments.
Civil but impassioned dialogue involving persons holding
strong, divergent views is in the best tradition of liberal
education and can break impasses where other means fail.
Forward thinking institutions should consider following
UCLA’s lead, creating forums where CAIM and main-
stream scientists can hash out responses to challenges both
face together.
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